NAMS
NAMS
NL00150012L7
NewAmsterdam Pharma Company N.V
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
2.58B EUR
3.99B EUR
3.73B EUR
4.01B EUR
Enterprise Value
1.91B EUR
3.56B EUR
3.28B EUR
3.52B EUR
Valuation Multiples
Trailing P/E
--
--
--
--
Forward P/E
-14.11x
--
--
--
Price to Sales
362.17x
559.92x
165.46x
205.54x
Price to Book
4.02x
6.31x
5.61x
5.87x
EV/Revenue
267.88x
500.37x
145.19x
180.45x
EV/EBITDA
-7.81x
--
--
--
Price to FCF (P/FCF)
--
--
--
--
EV/FCF
--
--
--
--
FCF Yield
-1.76%
-3.6%
-3.81%
-2.78%
ende